Biotechnology Value Trading Fund OS LP
CIK 1660683 · last filed 2025-05-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FPRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
GRAND CAYMAN, E9 KY1-1104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XOMA Royalty Corp (XOMAP) Delisted | 1,322,758 | $24.98 | $33.04M | -$106.43M | 1 | 2025-05-20 | |
| KYMR | Director | 1,888,351 | $114.84 | $216.86M | $0 | 1 | 2023-06-20 |
| GPCR | 0 | $21.10 | $0 | $0 | 1 | 2023-05-12 | |
| Repare Therapeutics Inc. (RPTX) Delisted | 3,299,906 | $2.65 | $8.74M | $18.99M | 1 | 2022-06-15 | |
| CGEM | 364,161 | $14.54 | $5.29M | $82.65M | 1 | 2022-06-03 | |
| CTI BIOPHARMA CORP (CTIC) Delisted | 3,102,435 | $9.09 | $28.20M | $50.00M | 2 | 2021-04-05 | |
| Merus N.V. (MRUS) Delisted | 3,513,335 | $90.00 | $316.20M | $209.06M | 1 | 2021-01-25 | |
| CYTK | 2,777,320 | $60.73 | $168.67M | $0 | 1 | 2020-11-20 | |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 670,695 | $38.00 | $25.49M | -$1.49B | 2 | 2020-11-13 | |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 32,062 | $15.70 | $503.4K | $25.65M | 1 | 2020-11-03 | |
| XOMA Royalty Corp (XOMA) Delisted | 2,022,816 | $40.17 | $81.26M | $4.31M | 3 | 2020-09-10 | |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 952,859 | $8.37 | $7.98M | -$28.94M | 1 | 2019-06-12 | |
| XENE | 216,694 | $35.77 | $7.75M | $0 | 1 | 2018-03-29 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 2,968,487 | $0.04 | $132.7K | $14.06M | 1 | 2017-10-05 |
Recent Filings · Page 2 of 2
20 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-20 | CYTK | Other (J) | — | $0 | EDGAR |
| 2020-11-13 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Sell (S) | −73,933,400 | -$1.49B | EDGAR |
| 2020-11-03 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +9,326,120 | $25.65M | EDGAR |
| 2020-09-10 | XOMA Royalty Corp (XOMA) Delisted | Buy (P) | +77,370 | $1.45M | EDGAR |
| 2020-04-17 | XOMA Royalty Corp (XOMA) Delisted | Conv (C) | +12,527,720 | $162.86M | EDGAR |
| 2019-10-31 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +205,198 | $796.7K | EDGAR |
| 2019-06-12 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Sell (S) | −2,704,023 | -$28.94M | EDGAR |
| 2019-05-14 | XOMA Royalty Corp (XOMA) Delisted | Buy (P) | +195,391 | $2.86M | EDGAR |
| 2018-03-29 | XENE | Other (J) | −17,059,000 | $0 | EDGAR |
| 2017-10-05 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +11,200,322 | $14.06M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.